Biologic Drugs With Established Pharmaceutical Class: CD38-directed Cytolytic Antibody
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: CD38-directed Cytolytic Antibody
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 2015-11-16 | ⤷ Get Started Free | ⤷ Get Started Free |
| Sanofi-aventis U.s. Llc | SARCLISA | isatuximab-irfc | Injection | 761113 | 2020-03-02 | ⤷ Get Started Free | ⤷ Get Started Free |
| Janssen Biotech, Inc. | DARZALEX FASPRO | daratumumab and hyaluronidase-fihj | Injection | 761145 | 2020-05-01 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
